interleukin-1beta (163-171) has been researched along with Premature Rupture of Fetal Membranes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayakawa, H; Ino, K; Kajiyama, H; Kikkawa, F; Mano, Y; Nawa, A; Shibata, K; Sumigama, S; Yamamoto, E | 1 |
1 other study(ies) available for interleukin-1beta (163-171) and Premature Rupture of Fetal Membranes
| Article | Year |
|---|---|
Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes.
Topics: Amnion; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blotting, Western; Cell Line; Epithelial Cells; Female; Fetal Membranes, Premature Rupture; Humans; Immunohistochemistry; Interleukin-1beta; Interleukin-6; Interleukin-8; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Peptide Fragments; Pregnancy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2009 |